Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637221 · ClinicalTrials.gov registry record · Phase 1
Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome
A Phase 1 study, sponsored by Neuropharm.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00637221 is a Phase 1 study that has completed, run by Neuropharm. The registered enrollment target is 12 participants.
The verdict
NCT00637221, a Phase 1 study, has completed, sponsored by Neuropharm.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open label exploratory study to investigate the safety and effects of a single dose of NPL-2009(50 mg - 150 mg) on Prepulse Inhibition (PPI) Tests and Continuous Performance Tasks (CPT) in adults with Fragile X Syndrome
Interventions
- DRUG NPL-2009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637221
The ClinicalTrials.gov registry entry for NCT00637221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuropharm, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NPL-2009 is the first listed.
NCT00637221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637221 about?
NCT00637221 is a clinical study titled "Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome". This is an open label exploratory study to investigate the safety and effects of a single dose of NPL-2009(50 mg - 150 mg) on Prepulse Inhibition (PPI) Tests and Continuous Performance Tasks (CPT) in adults with Fragile X Syndrome
What is the current status of trial NCT00637221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-03. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00637221?
The interventions under investigation include: NPL-2009 (DRUG).
Who is sponsoring clinical trial NCT00637221?
This trial is sponsored by Neuropharm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.